# CNBX PHARMACEUTICALS INC. (CNBX) · Edgar & Edgarette company card

> Cnbx Pharmaceuticals (CNBX) saw revenue fall 100% in FY2025 to $0 million, operating margin null against a -3.8% median for pharmaceutical preparations, equity -13540% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1343009 · fiscal year ended 2025-08-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CNBX) · [JSON](https://www.pops4.com/boards/company/CNBX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -448.3%) |
| Net margin | -Infinity% |
| Operating cash flow | −$171,305 |
| Capital spending | — |
| Free cash flow | — |
| Cash | $15,111 |
| Long-term debt | — |
| Total assets | $18,437 |
| Total equity | −$2M |
| Equity ÷ assets | -13539.6% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -5456.18 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$171K in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: revenue down 100.0% on the year; operating margin null, down from -448.3%. Soundness: equity -13539.6% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median; growth -100.0% against 13.7%.

## Health Watch, last 12 months

- Item 4.01 Auditor change: 1, latest 2026-10-01 ([filing](https://www.sec.gov/Archives/edgar/data/1343009/000168316826007522/0001683168-26-007522-index.htm))

## Recent filings

- 8-K · filed 2026-10-01 · 4.01 Changes in Registrant's Certifying Accountant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1343009/000168316826007522/0001683168-26-007522-index.htm)
- 10-Q · filed 2026-06-24 · [filing](https://www.sec.gov/Archives/edgar/data/1343009/000168316826005078/0001683168-26-005078-index.htm)
- 10-Q · filed 2026-04-14 · [filing](https://www.sec.gov/Archives/edgar/data/1343009/000168316826002899/0001683168-26-002899-index.htm)
- 8-K · filed 2026-03-17 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1343009/000168316826001883/0001683168-26-001883-index.htm)
- 10-Q · filed 2026-01-14 · [filing](https://www.sec.gov/Archives/edgar/data/1343009/000168316826000285/0001683168-26-000285-index.htm)
- 10-K · filed 2025-12-01 · [filing](https://www.sec.gov/Archives/edgar/data/1343009/000168316825008736/0001683168-25-008736-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001343009.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1343009

## Cite

POPS4, Edgar & Edgarette: CNBX PHARMACEUTICALS INC. (CNBX) company card, from the company's own SEC filings, accessed 2026-11-16, https://www.pops4.com/boards/company/CNBX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

